B‐cell–activating factor is elevated in serum of patients with myasthenia gravisopen access
- Authors
- Kang, Sa-Yoon; Kang, Chul-Hoo; Lee, Keun-Hwa
- Issue Date
- Dec-2016
- Publisher
- WILEY-BLACKWELL
- Keywords
- antibody; autoimmune; B-cell–activating factor; myasthenia gravis; pathogenesis; therapy
- Citation
- MUSCLE & NERVE, v.54, no.6, pp.1030 - 1033
- Indexed
- SCIE
SCOPUS
- Journal Title
- MUSCLE & NERVE
- Volume
- 54
- Number
- 6
- Start Page
- 1030
- End Page
- 1033
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/153326
- DOI
- 10.1002/mus.25162
- ISSN
- 0148-639X
- Abstract
- Introduction: Myasthenia gravis (MG) is a B-cell-mediated autoimmune disease. B-cell-activating factor (BAFF) is a major factor in B-cell development and activation. In this study we investigated serum BAFF levels in MG patients. Methods: We compared the serum BAFF levels of 20 MG patients with gender-matched healthy controls. We assayed serum concentrations of BAFF and anti-acetylcholine receptor antibody (AChR) titers. Results: Serum BAFF levels of MG patients with AChR antibodies were significantly higher than those of healthy controls. A significant positive correlation was observed between serum BAFF levels and anti-AChR antibody titers. BAFF values did not correlate with disease severity. Conclusions: BAFF may play a major role in the pathogenesis of MG, and it may provide a potential target for therapy in patients with MG.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 미생물학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/153326)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.